Company overview
Oxford Nanopore Technologies offers nanopore-based DNA/RNA sequencing platforms, including portable devices like MinION and high-throughput systems like PromethION, for life sciences and pharmaceutical R&D. These enable rapid, real-time molecular analysis with easy library preparation and compatibility with third-party products from partners such as 10x Genomics, Thermo Fisher Scientific, and Agilent. Distribution is supported globally through agreements like with Avantor for MinION devices in the US and Europe.
Nanoporetech is listed in the NovaPharmaNews Supplier Hub as a Diagnostics & Testing partner serving United States & Americas. Core focus areas include nanopore sequencing, dna rna sequencing, minion device, promethion, pharma sequencing.
Industry categories: Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://nanoporetech.com:443/
- Categories
- Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- nanopore sequencing, dna rna sequencing, minion device, promethion, pharma sequencing
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What sequencing platforms and capabilities does Oxford Nanopore offer?
- Oxford Nanopore provides nanopore sequencing products including portable MinION, GridION, and PromethION for DNA/RNA analysis, with rapid 10-minute library prep and real-time data output.
- What regulatory or validation processes support their products?
- Compatible third-party products undergo rigorous validation via the Compatible Products Programme, ensuring seamless integration and high performance with Oxford Nanopore platforms.
- In which geographies are Oxford Nanopore products distributed?
- Products like MinION are distributed globally, with Avantor handling US (including Puerto Rico), Europe (UK, Norway, Switzerland), and expansions to Canada.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
